Medicare Enrolled

Dr. Slavica Bobic

Rheumatology · St Petersburg, FL
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Low-engagement
710 94TH AVE N STE 306-307, St Petersburg, FL 33702
7272901444
In practice since 2015 (10 years)
NPI: 1760853469 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Bobic from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Bobic? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Bobic

Dr. Slavica Bobic is a rheumatology specialist in St Petersburg, FL, with 10 years of NPI registration. Based on federal Medicare data, Dr. Bobic performed 2,022 Medicare services across 401 unique beneficiaries.

Between the years covered by Open Payments, Dr. Bobic received a total of $5,936 from 32 pharmaceutical and/or device companies across 289 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Bobic is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 10 years in practice ▲ 2,022 Medicare services $5,936 industry payments

Medicare Practice Summary

Medicare Utilization ↗
2,022
Medicare services
Bottom 38% in FL for rheumatology
Lower Medicare volume may reflect subspecialty focus, hospital-based work, or a higher share of non-Medicare patients.
401
Unique beneficiaries
$43
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~202 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Denosumab injection (Prolia/Xgeva) 1,260 $18 $43
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
280 $90 $270
New patient office visit, complex (60-74 min) 153 $148 $521
Intravenous chemotherapy infusion, 1 hour or less
Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete.
102 $96 $345
Non-hormonal chemotherapy injection
This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue.
86 $54 $189
Additional hour of intravenous chemotherapy
This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period.
56 $21 $110
Intravenous injection of additional new drug or substance
Administration of an additional new medication or substance directly into a vein.
44 $12 $85
Methylprednisolone injection, up to 40 mg
An injection of methylprednisolone sodium succinate, a corticosteroid medication, administered in a dose of up to 40 mg.
41 $3 $13
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
5.0% high complexity
73.5% medium
21.4% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$5,936
Total received (2018-2024)
Avg $848/year across 7 years
Bottom 47% in FL for rheumatology
32
Companies
289
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,420 (91.3%)
Scientific / Research
Research funding and grants
$366 (6.2%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$150 (2.5%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$1,944
2023
$1,072
2022
$1,416
2021
$147
2020
$23
2019
$546
2018
$789

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Amgen Inc.
$1,127
Janssen Biotech, Inc.
$713
UCB, Inc.
$607
ABBVIE INC.
$538
Mallinckrodt Hospital Products Inc.
$536
Celgene Corporation
$315
PFIZER INC.
$272
Lilly USA, LLC
$202
Aurinia Pharma U.S., Inc.
$165
Regeneron Healthcare Solutions, Inc.
$145
AbbVie Inc.
$145
GlaxoSmithKline, LLC.
$120
Genentech USA, Inc.
$117
AstraZeneca Pharmaceuticals LP
$106
Fresenius Kabi USA, LLC
$94
AbbVie, Inc.
$86
E.R. Squibb & Sons, L.L.C.
$81
Horizon Therapeutics plc
$80
Boehringer Ingelheim Pharmaceuticals, Inc.
$78
SOBI, INC
$52
Sandoz Inc.
$51
Radius Health, Inc.
$45
Organon Llc
$38
GENZYME CORPORATION
$37
Sobi, Inc
$36
Fidia Pharma USA Inc.
$31
Exeltis, USA Inc.
$26
Mallinckrodt LLC
$25
Novartis Pharmaceuticals Corporation
$20
ANI Pharmaceuticals, Inc.
$19
Bioventus LLC
$17
Alexion Pharmaceuticals, Inc.
$13
Top 3 companies account for 41.2% of total payments
Associated products mentioned in payments ›
ACTHAR · AMJEVITA · Abraxane · BENLYSTA · Bimzelx · COSENTYX · Cimzia · Durolane · EVENITY · EVUSHELD · Enbrel · FORTEO · HADLIMA · HYM/HYN · HYMOVIS · HYRIMOZ · Humira · IDACIO · KEVZARA · KEVZARA SARILUMAB INJECTION · KINERET · KRYSTEXXA · Kineret · LUPKYNIS · ORENCIA · Otezla · PURIFIED CORTROPHIN GEL · RAYOS · REMICADE · RENFLEXIS · RINVOQ · Rituxan · SAPHNELO · SIMPONI ARIA · SKYRIZI · Strensiq · TALTZ · TAVNEOS · TREMFYA · Tymlos · XELJANZ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (91%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $294 per 100 Medicare services performed
Looking for a rheumatology specialist in St Petersburg?
Compare rheumatologists in the St Petersburg area by procedure volume, costs, and industry payment transparency.
Browse rheumatologists nearby

Geographic Context

Rheumatologists within 10 mi
56
Per 100K population
5.8
County median income
$70,293
Nearest hospital
ORLANDO HEALTH BAYFRONT HOSPITAL
5.2 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Bobic is a clinical cardiology specialist, with moderate Medicare volume, with low-engagement industry engagement.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Bobic experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Bobic performed 1,260 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Bobic receive payments from pharmaceutical companies?
Yes. Dr. Bobic received a total of $5,936 from 32 companies across 289 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Bobic's costs compare to other rheumatologists in St Petersburg?
Dr. Bobic's average Medicare payment per service is $43. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Bobic) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →